Common side effects (GLP-1 medications) Nausea Vomiting Diarrhea or constipation Reduced appetite to the point of under-eating Rare but serious risks may include: Pancreatitis Gallbladder issues Growth hormone-related peptides Potential risks: Fluid retention Joint pain Insulin resistance (if misused) Long-term unknowns For newer or research peptides, long-term data is limited
So when someone injects BPC-157 and feels better two weeks later, several explanations compete: time, rehabilitation, expectation (the person has just spent money on a peptide and perhaps publicly committed to trying it), and regression to the mean
Leonard Glass, senior vice president of global medical affairs at Eli Lilly Cardiometabolic Health, said in a release
We asked endocrinologist Kathy Zhou, MD, to explain why it happens and how you may be able to limit the loss
Table 3 summarizes RCTs of the dual and triple GLP1-RA use in obesity
Your Patient Care Coordinator is your dedicated point of contact, available to assist with appointment scheduling, questions, phone calls, and even secure text messaging